title: Role of linezolid in the treatment of resistant gram-positive infections.
abstract: Incidence of Gram-positive infections caused by bacteria resistant to commonly used antibiotics has increased in the last decades. Resistant strains appeared later in the Czech Republic, however their number has been increasing and new antibiotics have to be used. The greatest increase of frequency can be seen in infections caused by methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci. Vancomycin-resistant enterococci are usually found in hematooncology patients. Curative use of vancomycin is limited due to a narrow spectrum of activity, nephrotoxicity, and limited penetration into tissues (lung) and cerebrospinal fluid. Linezolid is a good option mainly in infections of skin and soft tissues, and it has an evincible advantage over vancomycin in the treatment of nosocomial pneumonia and surgical-site infections. Oral formulations are favourable allowing switch therapy and earlier discharge from hospital.
authors.affiliation: Department of Infectious,Hospital of Masaryk Ustí nad Labem, Czech Republic.
authors.forename: Pavel
authors.initials: P
authors.lastname: Dlouhý
authors.forename: Ivan
authors.initials: I
authors.lastname: Herold
authors.forename: Milan
authors.initials: M
authors.lastname: Kolár
authors.forename: Jirí
authors.initials: J
authors.lastname: Benes
authors.forename: Petr
authors.initials: P
authors.lastname: Cetkovský
authors.forename: Tomás
authors.initials: T
authors.lastname: Dolezel
authors.forename: David
authors.initials: D
authors.lastname: Jahoda
authors.forename: Michal
authors.initials: M
authors.lastname: Kouba
authors.forename: Ivan
authors.initials: I
authors.lastname: Novák
authors.forename: Otakar
authors.initials: O
authors.lastname: Nyc
authors.forename: Jan
authors.initials: J
authors.lastname: Pilnácek
authors.forename: Zdeneek
authors.initials: Z
authors.lastname: Rácil
authors.forename: Tomás
authors.initials: T
authors.lastname: Sechser
authors.forename: Pavel
authors.initials: P
authors.lastname: Sevcík
authors.forename: Petr
authors.initials: P
authors.lastname: Svihovec
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology; D018153:Czech Republic; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus; D013211:Staphylococcus aureus / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid